Facebook is reportedly censoring an article critical of the Trans-Pacific Partnership.
Within the first 30 minutes of its publication on Infowars.com, the article entitled TPP to Kill Thousands by Expanding Monopoly Power of Drug Companies would constantly hit around 50 shares on the embedded Facebook counter, but then the counter would drop dramatically, as shown in these videos (watch enlarged version here):
This occurred several times over the 30 minute period and an investigation by IT staff found nothing unusual that could be interfering with the counter.
Facebook was similarly censoring an anti-GMO article back in July.
“We’ve seen thousands of reports regarding the censorship of content by Facebook and others regarding the TPP, Monsanto and similar topics,” Anthony Gucciardi said regarding the censored article. “The bottom line here is that this article [was] being blocked across numerous platforms under the guise of a ‘security’ threat, when we know full well that these sites are perfectly safe.”
The social media giant was also suppressing an article exposing the “Pope Kid” incident in which amnesty activists staged a PR stunt involving Pope Francis to promote illegal immigration.
Not long after, Facebook CEO Mark Zuckerberg was caught discussing the censorship of anti-migrant posts with German Chancellor Angela Merkel.
“After being asked about Facebook’s efforts to curtail speech, Zuckerberg stated, ‘We need to do some work,’ confirming he’d already started looking at ways to hinder comments in opposition to Merkel’s immigration stance,” Mikael Thalen reported.
The most recent article apparently censored by Facebook revealed how the TPP gives signatory countries the ability to grant pharmaceuticals three years of “market exclusivity” for new uses of old medicines, preventing cheaper, genetic drugs from competing.
For example, the drug Zidovudine was first discovered as an effective cancer treatment in 1964 and years later, in 1987, it was also found to be effective against HIV, and under the TPP it would be illegal for generic drug makers to compete with the decades-old Zidovudine in the HIV market for at least three years.
“Zidovudine cost about $7,000 per person per year at the monopoly price (new HIV indication) when it was introduced while the price of the generic version (cancer indication) had fallen to $70 per person per year by June 2013,” government watchdog group Public Citizen reported. “This is an example of the kind of price differences which could occur in TPP countries if they choose this implementation option of providing three-year monopolies for new indications.”
Facebook has previously shown support for the TPP.